Claims for Patent: 8,338,485

Summary for Patent: 8,338,485

Title:	Compositions for the treatment of CNS-related conditions
Abstract:	The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
Inventor(s):	Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV)
Assignee:	Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:	13/536,588
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,338,485
Patent Claims:	1. A solid pharmaceutical composition in a unit dosage form for oral administration comprising: (a) an extended release formulation of 22.5 to 30 mg memantine or pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in concentration of memantine as a function of time (dC/dT) that is: (1) less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0-Tmax of the immediate release form of memantine; and (2) 2.1 ng/ml/hr or less, determined in a time period of 0 to 4 hours; and wherein dC/dT is measured in a single-dose human PK study; and (b) a therapeutically effective amount of immediate release donepezil. 2. The composition of claim 1, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 to 4 hours. 3. The composition of claim 1, comprising 25 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof. 4. The composition of claim 3, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 to 4 hours. 5. The composition of claim 1, comprising 25 mg to 28 mg memantine or a pharmaceutically acceptable salt thereof. 6. The composition of claim 5, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 to 4 hours. 7. The composition of claim 1, comprising 28 mg memantine or a pharmaceutically acceptable salt thereof. 8. The composition of claim 7, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 to 4 hours. 9. A solid pharmaceutical composition in a unit dosage form for oral administration comprising: (a) an extended release formulation of 22.5 to 30 mg memantine or pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in concentration of memantine as a function of time (dC/dT) that is: (1) less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours of administration of memantine; and (2) 2.1 ng/ml/hr or less, determined in a time period of 0 to 4 hours; and wherein dC/dT is measured in a single-dose human PK study; and (b) a therapeutically effective amount of immediate release donepezil. 10. The composition of claim 9, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 to 4 hours. 11. The composition of claim 9, comprising 25 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof. 12. The composition of claim 11, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 to 4 hours. 13. The composition of claim 9, comprising 25 mg to 28 mg memantine or a pharmaceutically acceptable salt thereof. 14. The composition of claim 13, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 to 4 hours. 15. The composition of claim 9, comprising 28 mg memantine or a pharmaceutically acceptable salt thereof. 16. The composition of claim 15, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 to 4 hours.